P erinatal asphyxial encephalopathy is associated with high morbidity and mortality rates worldwide and is a major burden for the patient, the family, and society. There is an urgent need to improve outcomes in affected infants.
Experimentally, reducing body temperature to 3 to 5°C below the normal level reduces cerebral injury and improves neurologic function after asphyxia. [1] [2] [3] [4] [5] [6] Preliminary clinical studies have found no serious adverse effects of cooling. [7] [8] [9] Two randomized, controlled trials, the CoolCap trial 10 and the National Institute of Child Health and Human Development (NICHD) trial, 11 have reported outcomes among infants at 18 months of age who had asphyxial encephalopathy, after slightly different cooling regimens. Only the NICHD trial showed a significant reduction in the composite primary outcome of death or disability with hypothermia. Neither trial had sufficient power to detect significant differences in important individual neurologic outcomes, and several systematic reviews and an expert workshop did not reach a consensus in recommending hypothermia as standard treatment. [12] [13] [14] [15] [16] [17] To clarify the role of hypothermia, we carried out the Total Body Hypothermia for Neonatal Encephalopathy Trial (TOBY), a multicenter, randomized trial comparing intensive care plus total-body cooling for 72 hours with intensive care without cooling among term infants with asphyxial encephalopathy.
Me thods
The TOBY protocol was approved by the London Multicenter Research Ethics Committee and the local research ethics committee of each participating hospital. Conduct of the study was overseen by an independent trial steering committee with advice from an independent data monitoring and ethics committee.
Study Design and Procedures
TOBY was a randomized, controlled trial, involving term infants, comparing intensive care plus total-body cooling for 72 hours with intensive care without cooling. Infants were eligible if they were born at or after 36 completed weeks' gestation. They also had to have, at 10 minutes after birth, either an Apgar score of 5 or less or a continued need for resuscitation or, within 60 minutes after birth, acidosis (defined as any occurrence of umbilical-cord, arterial, or capillary pH of <7.00 or base deficit of ≥16 mmol per liter). In addition, they had to have moderate-to-severe encephalopathy (indicated by lethargy, stupor, or coma) and either hypotonia, abnormal reflexes (including oculomotor or pupillary abnormalities), an absent or weak suck, or clinical seizures. Finally, they had to have abnormal background activity of at least 30 minutes' duration or seizures on amplitudeintegrated electroencephalography. 18 We excluded infants expected to be more than 6 hours of age at the time of randomization and those with major congenital abnormalities known at randomization that required surgery or were suggestive of chromosomal anomaly or syndromes that involve brain dysgenesis.
Written informed consent was obtained from a parent of each infant after explanation of the study, and consent was reaffirmed within the subsequent 24 hours. 19 Assignment to a treatment group was performed by means of central telephone randomization or a secure Web-based system (provided by the National Perinatal Epidemiology Unit Clinical Trials Unit, Oxford, United Kingdom). Minimization was used to ensure balance of treatment assignment among infants with various grades of abnormality on amplitude-integrated electroencephalography and within each participating center.
Clinical Management
All recruited infants were cared for in participating centers. Infants from referring hospitals were assessed by trained retrieval teams who performed amplitude-integrated electroencephalography, sought consent if the infant was eligible, performed randomization, and for infants assigned to the cooled group, began cooling by discontinuing warming and applying cooled gel packs, if necessary, until the infant was admitted to a participating center.
To minimize potential confounding from differential use of cointerventions, uniform guidance was provided on ventilatory and circulatory care, management of seizures, sedation, and fluid requirements. All infants underwent sedation with morphine infusions or with chloral hydrate if they appeared to be distressed. Skin temperature and rectal temperature (measured at least 2 cm within the rectum) were monitored continuously and recorded hourly in all infants throughout the inter-vention period. Clinical staff were made aware of the treatment assignments so that they could manage cooling appropriately.
Intensive Care Alone
Infants assigned to the noncooled group received the current standard of care and were placed under radiant heaters or in incubators, which were servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0±0.2°C.
Intensive Care with Cooling
Infants assigned to the cooled group were treated in incubators with the power turned off. Hypothermia was maintained by nursing the infant on a cooling blanket in which fluid whose temperature was regulated by a manually adjusted thermostat (Tecotherm TS 200, Tec-Com) was circulated. The target rectal temperature was 33 to 34°C, and typically, the thermostat was set from 25 to 30°C.
Rewarming Procedures
When the period of cooling concluded, 72 hours after randomization, the rectal temperature was monitored for at least 4 hours to prevent rebound hyperthermia. The rectal temperature was allowed to rise by no more than 0.5°C per hour, to a maximum of 37±0.2°C. Cranial ultrasonography was performed daily for the first 4 days after birth, and magnetic resonance imaging (MRI) was conducted, according to a specified protocol, within 5 to 14 days after birth.
Outcomes
The primary outcome at 18 months of age was a composite of death or severe neurodevelopmental disability in survivors. Severe neurodevelopmental disability was defined as a score of less than 70 on the Mental Developmental Index of the Bayley Scales of Infant Development II (BSID-II) (on which the standardization mean [±SD] is 100±15 and higher scores indicate better performance), a score of 3 to 5 on the Gross Motor Function Classification System 20 (GMFCS) (on which scores can range from 1 to 5, with higher scores indicating greater impairment), or bilateral cortical visual impairment with no useful vision.
Adverse outcomes included intracranial hemorrhage, persistent hypotension, pulmonary hemorrhage, pulmonary hypertension, prolonged blood coagulation time, culture-proven sepsis, necrotizing enterocolitis, cardiac arrhythmia, thrombocytopenia, major venous thrombosis, renal failure treated with dialysis, pneumonia, pulmonary air leak, and duration of hospitalization. (Most outcomes are defined in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
Secondary outcomes at 18 months, specified before data analysis, included death and severe neurodevelopmental disability (components of the composite primary outcome), the score on the Psychomotor Developmental Index of BSID-II (on which the standardization mean [±SD] is 100±15 and higher scores indicate better performance), cerebral palsy, hearing loss, seizures treated with anticonvulsant agents, microcephaly (i.e., age-and sex-standardized head circumference of more than 2 SD below the mean), multiple neurodevelopmental abnormalities (i.e., more than one of the following: a GMFCS score of 3 to 5, a score of <70 on the Mental Developmental Index of BSID-II) (on which the standardization mean [±SD] is 100±15 and higher scores indicate better performance, seizures, or cortical visual impairment and hearing loss), and survival without neurologic abnormality (i.e., a Mental Developmental Index score >84, a Psychomotor Developmental Index score >84, no abnormalities on GMFCS assessment, and normal vision and hearing).
Neurologic Assessment
Infants were assessed at approximately 18 months of age, through a structured examination by one of five trained assessors who were unaware of the treatment assignments. Neurologic signs and function were scored, 20,21 and the presence and type of cerebral palsy were determined. Neurodevelopmental outcome was assessed according to the BSID-II. 22
Statistical Analysis
We estimated that a sample of 236 infants would be required to detect a relative risk of 0.6 to 0.7 for the primary outcome in the cooled group as compared with the noncooled group, with a statistical power of 80%, at a two-sided significance level of 5% and assuming a 10% loss to follow-up. This sample size was achieved ahead of schedule, and enrollment was continued after the CoolCap and NICHD trial results suggested that a larger sample would be valuable.
Demographic and clinical characteristics were summarized at baseline as counts and percentages of the total numbers of infants for categorical vari-ables, as means (±SD) for normally distributed continuous variables, and as medians and ranges or interquartile ranges for other continuous variables.
Data were analyzed in the groups to which patients had been assigned regardless of either deviation from the protocol or treatment received. Consistent with previous reports, 10,11 neurologic outcomes are presented for survivors who had available follow-up data.
Comparative statistical analysis entailed calculating the relative risks plus the 95% confidence intervals for all dichotomous outcomes, the mean differences plus 95% confidence intervals for normally distributed, continuous outcomes (using analysis of covariance where appropriate), and the median differences plus 95% confidence intervals for skewed continuous variables. In addition, ordered categorical variables were examined with the use of the chi-square test for trend. An adjusted analysis of the primary outcome was performed to investigate the effect of known prognostic factors. All statistical tests were two-sided and were not adjusted for multiple comparisons.
Prespecified subgroup analyses were performed with stratification on the basis of the grade of abnormality on amplitude-integrated electroencephalography at randomization and duration of the interval between birth and randomization (0 to <4 hours vs. 4 to 6 hours). The consistency of the effect of the treatment group across subgroups was explored by means of the statistical test of interaction.
R esult s
From December 1, 2002 , through November 30, 2006 , 494 infants were screened and 325 were recruited from 42 hospitals (Fig. 1) . The infants were from the United Kingdom (277), Hungary (24) , Sweden (18), Israel (4), and Finland (2). Baseline characteristics of the infants (including maternal characteristics) were broadly similar between the two groups ( Table 1) .
Compliance with Cooling Protocol
Rectal temperatures were similar between the two groups at the time of randomization (Table 1) .
Mean rectal temperatures at 6 to 72 hours after randomization were 33.5±0.5°C and 36.9±0.6°C in the cooled and noncooled groups, respectively (Fig. 2) . Among the 162 infants who were not cooled, during the treatment period the temperature rose above 38°C on one occasion in 14 (9%) and on more than one occasion in 23 (14%).
Primary Outcome
In the cooled group, 42 infants died and 32 survived with severe neurodevelopmental disability, whereas in the noncooled group, 44 infants died and 42 had severe disability (Table 2 ) (relative risk for either outcome, 0.86; 95% confidence interval [CI], 0.68 to 1.07; P = 0.17). The result was materially unchanged when adjusted for severity of abnormality on amplitude-integrated electroencephalography, sex, or age at randomization.
Adverse Outcomes
The incidence of adverse events was similar in the two groups (Table 3) . Hypotension, thrombocytopenia, prolonged coagulation time, and intracranial hemorrhage (seen only on MRI) were frequently observed in both groups. Serious adverse events other than death were uncommon and were not associated with cooling. Two infants in the cooled group and one in the noncooled group had sinus thrombosis noted on MRI. Another infant in the cooled group had a thrombus in the aorta, as well as an umbilical arterial catheter and a hematocrit of 70%. No case of renal failure requiring dialysis occurred.
Secondary Outcomes at 18 Months
The mortality rate was similar in both groups. Forty-two infants in the cooled group died, as did 44 infants in the noncooled group; in each group, 39 of those died before hospital discharge. Death occurred after the withdrawal of care in 34 of the 39 (87%) in the cooled group and 29 of the 39 (74%) in the noncooled group. Outcomes were significantly improved in the cooled group with regard to 5 of the 12 secondary neurologic outcomes assessed ( However, the effect of cooling did not significantly vary according to the severity of abnormality on amplitude-integrated electroencephalography (P = 0.23 for interaction). The results were similar when the analysis was carried out with the results of amplitude-integrated electroencephalography classified as in the CoolCap study. 10 The effect of treatment group did not vary significantly on the basis of time to randomization: among the 105 infants randomly assigned to a group less than 4 hours after birth, the relative risk for the primary outcome with cooling was 0.77 (95% CI, 0.44 to 1.04), whereas among the 220 remaining infants who were randomly assigned between 4 and 6 hours after birth, the relative risk was 0.95 (95% CI, 0.72 to 1.25; P = 0.21 for interaction).
Discussion
In this trial of near-term infants with perinatal asphyxia, we found no significant difference in the risk of the primary outcome, the combined rates of death or severe disability, between the cooled group and the noncooled group. However, cooling resulted in consistent improvement in secondary outcomes, including a significant increase in the rate of survival without neurologic abnormalities and improved neurodevelopmental outcomes among survivors. The primary outcome of TOBY, as in the CoolCap and NICHD trials, was a composite end point, chosen because of concerns that cooling might increase survival with additional disability. Results of all three trials are consistent with respect to this primary outcome, with point estimates supporting a benefit from hypothermia: the relative risk associated with cooling (vs. no cooling) was 0.82 (95% CI, 0.66 to 1.02) in the CoolCap study, 0.72 (95% CI, 0.71 to 0.93) in the NICHD trial (which included infants with moderate disability), and 0.86 (95% CI, 0.68 to 1.07) in the present trial.
Our categorization of neurologic outcomes is consistent with that used in the CoolCap and NICHD trials and previous systematic reviews, [12] [13] [14] [15] [16] [17] facilitating the comparison of our findings with previous results. We found a significant increase in the rate of survival without neurologic abnormality with cooling (relative risk, 1.57; 95% CI, 1.16 to 2.12); the NICHD and CoolCap trials, which were smaller than the present trial, showed nonsignificant benefits with regard to this out- Although there is striking homogeneity among results of these three trials, there are also some differences. Only the NICHD trial detected a significant effect of hypothermia on the primary outcome, and only TOBY detected significant improvements in specific neurologic outcomes. Both TOBY and the CoolCap trial showed that the increased risk of death or severe disability in infants with the most abnormal grade on amplitudeintegrated electroencephalography was unaffected by cooling, but the CoolCap results suggested a reduction of the risk in the subgroup with less severely abnormal findings.
These discrepancies among results may be explained in part by differences in the trial protocols. In all three trials, the whole-body temperature (as measured in the rectum or esophagus) was reduced, but the strategies for cooling and the target temperatures varied: temperature was decreased to 33 to 34°C with the use of cooling blankets in TOBY and the NICHD trial and to 34 to 35°C by means of scalp cooling in the CoolCap study. The NICHD trial recorded slightly higher temperatures in the control group than did the other two trials. In TOBY, but not the other two trials, cooling was initiated during transport to the treatment center. In TOBY and the CoolCap trial, but not the NICHD trial, patients were selected on the basis of the presence of abnormalities on amplitude-integrated electroencephalography in addition to clinical criteria. Differences in local practices for withdrawal of care may also have affected outcomes. Withdrawal was slightly more common in the control group than in the cooled group in the NICHD study but was more common in the cooled group than in the control group in TOBY; these results may partially account for the greater apparent effect of hypothermia on mortality rate in the NICHD study as compared with TOBY. Elevation of body temperature to greater than 38°C was observed in several noncooled infants in the NICHD and CoolCap trials and was associated with a worse outcome in the CoolCap trial. 11,24 A rectal temperature of more than 38°C was also noted in some noncooled infants in TOBY. Experimental data showing that pyrexia may adversely affect neurodevelopment support the possibility that increased temperatures may contribute to the poorer outcomes seen in the noncooled groups; however, it is also possible that the relationship between higher elevation of body temperature and poor outcome reflects reverse causation (i.e., asphyxia resulting in impairment of temperature regulation).
Consistent with findings in the earlier trials, in our study, minor respiratory and cardiovascular events were common, but serious adverse events were rare and were not associated with cooling. Mild-to-moderate intracranial hemorrhage that was not visible on cranial ultrasonography was frequently seen on MRI in both groups, and sinus thrombosis occurred very infrequently in both groups.
No trial, to our knowledge, has yet reported neurologic outcomes at ages older than 18 months. Neurodevelopmental assessments at 18 months may not reliably predict later outcomes. 25 Although it is likely that severe neuromotor disability will have been correctly identified at 18 months, less severe impairments are not reliably assessable at this age. Assessment later in childhood (e.g., at 6 to 7 years of age) is necessary for accurate, comprehensive evaluation of cognitive function, behavior and learning, fine motor development, attention, and psychosocial health. 26 In conclusion, TOBY did not show a significant reduction in the combined rates of death and severe disability with cooling, as compared with no cooling, but did show a significant improvement in several secondary neurologic outcomes among survivors. Whether this improvement is maintained in the longer term needs to be ascertained.
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